Compare HMY & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMY | KYMR |
|---|---|---|
| Founded | 1950 | 2015 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 10.6B |
| IPO Year | 2002 | 2020 |
| Metric | HMY | KYMR |
|---|---|---|
| Price | $19.20 | $119.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 26 |
| Target Price | $16.00 | ★ $107.72 |
| AVG Volume (30 Days) | ★ 3.2M | 649.1K |
| Earning Date | 02-04-2016 | 04-30-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,211,000.00 |
| Revenue This Year | $37.43 | $10.61 |
| Revenue Next Year | $27.44 | $8.17 |
| P/E Ratio | $15.60 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.03 | $40.10 |
| 52 Week High | $26.04 | $130.05 |
| Indicator | HMY | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 48.46 | 52.58 |
| Support Level | $19.19 | $108.87 |
| Resistance Level | $19.69 | $120.37 |
| Average True Range (ATR) | 0.68 | 4.70 |
| MACD | -0.33 | -0.55 |
| Stochastic Oscillator | 5.57 | 42.92 |
Harmony Gold Mining Co Ltd is engaged in gold mining and related activities, including exploration, extraction, and processing. The group's primary product is gold bullion, produced at operations in South Africa and Papua New Guinea. Gold byproducts include uranium and silver. Strategic projects such as the Wafi-Golpu Project in the New Guinea Mobile Belt, the Eva Copper Project in the Mt Isa Inlier, Queensland, Australia, and the MAC Copper acquisition position the company as a gold-copper producer. The company operates across South Africa, Papua New Guinea, and Australia.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.